
Description: This market report gives a comprehensive and easy-to-review analysis of the liquid biopsy market 2016 - 2020. It provides key market data and identifies new and emerging opportunities relating to circulating tumour cells (CTCs) and circulating cell-free DNA and RNA (cfDNA and cfRNA).

The analysis is based on primary data disclosed by experienced end-users’ in the clinical, diagnostics and research fields on their current liquid biopsy practices and their plans over the next three. Its findings provide a wealth of market information on the liquid biopsy market and enables suppliers to reduce costs, identify new markets and compete more effectively in the global marketplace.

Circulating Tumour Cells (CTCs)

- Current and 3-year CTC activity disclosures provided by 482 scientists and clinicians
- Growth in CTC tests and estimated growth over the next 3 years (±% change)
- End-users’ estimates of the costs per patient, for CTC tests
- CTC detection/enrichment platforms used currently and in 3 years (±% change)
- Company CTC platforms used currently and over the next 3 years (±% change)
- CTC parameters or measurements now and in 3 years (±% change)
- Non-Molecular techniques used with CTCs, currently and in 3 years (±% change)
- Molecular techniques used with CTCs, now and in 3 years (±% change)
- Suppliers of molecular techniques currently and anticipated in 3 years (±% change)
- Markers used to enrich or characterise CTCs now and in 3 years (±% change)
- CTC subpopulation studies currently and anticipated in 3 years (±% change)
- Molecular forms studied currently and anticipated in 3 years (±% change)
- Molecular biomarkers studied currently and anticipated in 3 years (±% change)
- Sample types studied currently for the purpose of CTC studies
- End-users’ disclosures on the clinical utilities of CTCs in diagnostics
- Cancer types studied relating to the study of CTCs
- Purpose of studies relating to CTCs
- Limitations of current studies of CTCs
- Fields or sectors
- Global regions, countries and organisation types
- The study or investigation of CTCs in drug R&D
- The study or investigation of CTC in drug R&D by R&D development phase
- The use of CTCs as companion diagnostics now and in 3 years (±% change)

Free Circulating Nucleic Acids (CNAs)

- Growth in cfDNA and cfRNA tests and over the next 3 years (±% change)
- Cost estimates per sample, by scientists and clinicians, for patient CNA tests
- Molecular techniques used with cfDNA and cfRNA, now and in 3 years (±% change)
- Suppliers of molecular techniques currently and anticipated in 3 years (±% change)
- Suppliers of kits for the enrichment or isolation of cfDNA and cfRNA
- Molecular forms studied currently and anticipated in 3 years (±% change)
- Biomarkers studied currently and anticipated in 3 years (±% change)
- Sample types studied for cfDNA and cfRNA now and in 3 years (±% change)
- Clinical utilities of cfDNA and cfRNA in diagnostics now and in 3 years (±% change)
- Disease types studied relating to the study of cfDNA and cfRNA
- Cancer types studied relating to the study of cfDNA and cfRNA
- Purpose of studies relating to cfDNA and cfRNA
- Limitations of current studies of cfDNA and cfRNA
- Fields or sectors
- Global regions, countries and organisation types
- End-users’ cfDNA and cfRNA studies in drug R&D now and 3 years (±% change)
- End-users’ cfDNA and cfRNA studies in drug R&D by R&D development phase
Recent years have seen the rapid development of minimally invasive diagnostic techniques in the cancer field, notably relating to so-called 'liquid biopsies'. These developments have included the study and characterisation of circulating tumour cells and (CTCs) and circulating cell-free nucleic acids (cfDNA and cfRNA). Today, around 50 companies offer techniques that image, enrich, isolate or characterise CTCs and more advanced methods are also being used to isolate and characterise cfDNA and cfRNA. Advances are also being seen in the study of CTC sub-populations, time-dependent changes and the markers used to isolate or enrich them and new methods are increasingly being applied to cfDNA and cfRNA. Both of these strategies are seeing rapid development, as researchers and developers seek to translate these methodologies and the findings they are providing, into diagnostic tests that impact on clinical care or which drive new discovery.

Nevertheless, despite the excitement these developments are creating, important and fundamental questions remain unanswered. Laboratory Markets Ltd has carried out two comprehensive studies of diagnostic developments relating to CTCs, cell-free nucleic acids (cfDNA and cfRNA) and exosomes. These were carried out to help address these questions and to assist diagnostic companies to identify and support evolving diagnostic needs in these growing fields.

This report presents the findings of a new 'liquid biopsy' market study on CTCs, circulating cell-free nucleic acids and exosomes, completed in December 2015. These findings are analysed alongside results of a study of these markets, completed eighteen months earlier. Findings from these two studies, which present the disclosures of experienced researchers and clinicians in these fields, allowed an in-depth analysis of new developments and trends being seen in these growing diagnostic market areas.

The current studies profiled 482 experienced clinicians and research scientists, and covered CTC and cfDNA and cfRNA current practices, developments, trends and three-year plans, as well as growth, shrinkage and opportunities across key areas of these diagnostic markets. Its findings provide diagnostic companies with market information on the current and evolving use of CTCs and cfDNA and cfRNA, as well as exosomes, and the techniques that are driving these developments.

Our specialised market studies are designed to assist diagnostic companies and developers to profile current and evolving market opportunities. All of our studies are carried out through specialist groups of experienced researchers and clinicians, and therefore findings are based on 'real world' market data. By providing new insights and a better understanding of end-user practices, needs and future plans, our studies help companies identify qualified leads, to sell into these markets and also support innovation and strategic planning.
2.3 Countries

Figure 2.3. Top ten countries of participants in CircBio 2015
Table 2.3. Countries of participants in CircBio 2015
Figure 2.4. Top ten countries of participants in CircBio 2015 (Study 1)
Table 2.4. Countries of participants in CircBio 2015 (Study 1)

2.4 Organisation Types

Figure 2.5. Organisation types of participants in CircBio 2015
Table 2.5. Organisation types of participants in CircBio 2015
Figure 2.6. Organisation types of participants in CircBio 2015 (Study 1)
Table 2.6. Organisation types of participants in CircBio 2015 (Study 1)

2.5 Role

Figure 2.7. Roles of participants in CircBio 2015
Table 2.7. Roles of participants in CircBio 2015
Figure 2.8. Roles of participants in CircBio 2015 (Study 1)
Table 2.8. Roles of participants in CircBio 2015 (Study 1)

2.6 Experience

Figure 2.9. Top ten experience levels of participants in CircBio 2015
Table 2.9. Experience of participants in CircBio 2015
Figure 2.10. Top ten experience levels of participants in CircBio 2015 (Study 1)
Table 2.10. Experience of participants in CircBio 2015 (Study 1)

2.7 Discussion

Chapter 3. Area Of Work

3.1 This Chapter
3.2 Area of Work

Figure 3.1. Area of work of participants in CircBio 2015 participants
Table 3.1. Area of work of participants in CircBio 2015 participants
Figure 3.2. Area of work of participants in CircBio 2015 participants (Study 1)
Table 3.2. Area of work of participants in CircBio 2015 participants (Study 1)

Chapter 4. Circulating Tumour Cells

4.1 This Chapter
4.2 Role of Participant

Figure 4.1. Role of CircBio 2015 participants in the cancer field, who study CTCs in their work.
Table 4.1. Role of CircBio 2015 participants in the cancer field, who study CTCs in their work.
Figure 4.2. Role of CircBio 2015 participants in the cancer field, who study CTCs in their work (Study 1)
Table 4.2. Role of CircBio 2015 participants in the cancer field, who study CTCs in their work (Study 1)

4.3 Current Purposes

Figure 4.3. Top ten current main purpose(s) of their work, relating to CTCs, of CircBio 2015 participants
Table 4.3. Current main purpose(s) of their work, relating to CTCs, of CircBio 2015 participants
Figure 4.4. Top ten current main purpose(s) of their work, relating to CTCs, of CircBio 2015 participants (Study 1)
Table 4.4. Current main purpose(s) of their work, relating to CTCs, of CircBio 2015 participants (Study 1)

4.4 Future Purposes

Figure 4.5. Top ten future main purpose(s) of their work, relating to CTCs, of CircBio 2015 participants
Table 4.5. Future main purpose(s) of their work, relating to CTCs, of CircBio 2015 participants
Figure 4.6. Top ten future main purpose(s) of their work, relating to CTCs, of CircBio 2015 participants (Study 1)
1) Table 4.6. Future main purpose(s) of their work, relating to CTCs, of CircBio 2015 participants (Study 1)

4.5. Current Cancers

Figure 4.7. Top ten current cancers investigated in their work, relating to CTCs, of CircBio 2015 participants
Table 4.7. Current cancers investigated in their work, relating to CTCs, of CircBio 2015 participants
Figure 4.8. Top ten current cancers investigated in their work, relating to CTCs, of CircBio 2015 participants (Study 1)
Table 4.8. Current cancers investigated in their work, relating to CTCs, of CircBio 2015 participants (Study 1)

4.6. Future Cancer

Figure 4.9. Top ten future cancers investigated in their work, relating to CTCs, of CircBio 2015 participants
Table 4.9. Future cancers investigated in their work, relating to CTCs, of CircBio 2015 participants
Figure 4.10. Top ten future cancers investigated in their work, relating to CTCs, of CircBio 2015 participants (Study 1)
Table 4.10. Future cancers investigated in their work, relating to CTCs, of CircBio 2015 participants (Study 1)

4.7. Current Samples

Figure 4.11. Top ten current sample types investigated in their work, relating to CTCs, of CircBio 2015 participants
Table 4.11. Current sample types investigated in their work, relating to CTCs, of CircBio 2015 participants
Figure 4.12. Top ten current sample types investigated in their work, relating to CTCs, of CircBio 2015 participants (Study 1)
Table 4.12. Current sample types investigated in their work, relating to CTCs, of CircBio 2015 participants (Study 1)

4.8. Future Samples

Figure 4.13. Top ten future sample types investigated in their work, relating to CTCs, of CircBio 2015 participants
Table 4.13. Future sample types investigated in their work, relating to CTCs, of CircBio 2015 participants
Figure 4.14. Top ten future sample types investigated in their work, relating to CTCs, of CircBio 2015 participants (Study 1)
Table 4.14. Future sample types investigated in their work, relating to CTCs, of CircBio 2015 participants (Study 1)

4.9. Study of CTC Sub-Populations

Figure 4.15. CircBio 2015 participants' study of CTC sub-populations in their CTC work
Table 4.15. CircBio 2015 participants' study of CTC sub-populations in their CTC work
Figure 4.16. CircBio 2015 participants' study of CTC sub-populations in their CTC work (Study 1)
Table 4.16. CircBio 2015 participants' study of CTC sub-populations in their CTC work (Study 1)

4.10. Current CTC Sub-Populations

Figure 4.17. Top ten current CTC subpopulations studied, for those CircBio 2015 participants who answered 'yes' to the previous question
Table 4.17. Current CTC subpopulations studied, for those CircBio 2015 participants who answered 'yes' to the previous question
Figure 4.18. Top ten current CTC subpopulations studied, for those CircBio 2015 participants who answered 'yes' to the previous question (Study 1)
Table 4.18. Current CTC subpopulations studied, for those CircBio 2015 participants who answered 'yes' to the previous question (Study 1)

4.11. Future CTC Sub-Populations

Figure 4.19. Top ten future anticipated CTC subpopulations to be studied, by those CircBio 2015 participants who answered 'yes' to the previous question
Table 4.19. Future CTC subpopulations anticipated studied, by those CircBio 2015 participants who answered 'yes' to the previous question
4.12. Future Study of CTC Sub-Populations

Figure 4.21. The future anticipated study of CTC subpopulations, by those CircBio 2015 participants who answered 'No' to the previous question (see sections 4.10)
Table 4.21. The future anticipated study of CTC subpopulations, by those CircBio 2015 participants who answered 'No' to the previous question (see sections 4.10)
Figure 4.22. The future anticipated study of CTC subpopulations, by those CircBio 2015 participants who answered 'No' to the previous question (see sections 4.10) (Study 1)
Table 4.22. The future anticipated study of CTC subpopulations, by those CircBio 2015 participants who answered 'No' to the previous question (see sections 4.10) (Study 1)

4.13. Current CTC Measurements

Figure 4.23. Current CTC measurements used by CircBio 2015 participants, in their CTC studies
Table 4.23. Current CTC measurements used by CircBio 2015 participants, in their CTC studies
Figure 4.24. Current CTC measurements used by CircBio 2015 participants, in their CTC studies (Study 1)
Table 4.24. Current CTC measurements used by CircBio 2015 participants, in their CTC studies (Study 1)

4.14. Future CTC Measurements

Figure 4.25. Future anticipated CTC measurements of CircBio 2015 participants, in their CTC studies.
Table 4.25. Future anticipated CTC measurements of CircBio 2015 participants, in their CTC studies.
Figure 4.26. Future anticipated CTC measurements of CircBio 2015 participants, in their CTC studies (Study 1)
Table 4.26. Future anticipated CTC measurements of CircBio 2015 participants, in their CTC studies (Study 1)

4.15. Current CTC Markers

Figure 4.27. Top ten current CTC markers studied by CircBio 2015 participants, in their CTC studies
Table 4.27. Current CTC markers studied by CircBio 2015 participants, in their CTC studies
Figure 4.28. Top ten current CTC markers studied by CircBio 2015 participants, in their CTC studies (Study 1)
Table 4.28. Current CTC markers studied by CircBio 2015 participants, in their CTC studies (Study 1)

4.16. Future CTC Markers

Figure 4.29. Top ten future CTC markers anticipated to be studied by CircBio 2015 participants, in their CTC studies
Table 4.29. Future CTC markers anticipated to be studied by CircBio 2015 participants, in their CTC studies
Figure 4.30. Top ten future CTC markers anticipated to be studied by CircBio 2015 participants, in their CTC studies (Study 1)
Table 4.30. Future CTC markers anticipated to be studied by CircBio 2015 participants, in their CTC studies (Study 1)

4.17. Current CTC Enrichment, Isolation or Detection Methods

Figure 4.31. Top ten current CTC enrichment, isolation or detection methods used by CircBio 2015 participants, in their CTC studies
Table 4.31. Current CTC enrichment, isolation or detection methods used by CircBio 2015 participants, in their CTC studies
Figure 4.32. Top ten current CTC enrichment, isolation or detection methods used by CircBio 2015 participants, in their CTC studies (Study 1)
Table 4.32. Current CTC enrichment, isolation or detection methods used by CircBio 2015 participants, in their CTC studies (Study 1)

4.18. Current CTC Enrichment, Isolation or Detection Methods

Figure 4.33. Top ten current CTC enrichment, isolation or detection methods used by CTC cfDNA-RNA 2015 participants, in their CTC studies
Table 4.33. Current CTC enrichment, isolation or detection methods used by CTC cfDNA-RNA 2015
participants, in their CTC studies
Figure 4.34. Top ten current CTC enrichment, isolation or detection methods used by CTC cfDNA-RNA 2015 participants, in their CTC studies (Study 1)
Table 4.34. Current CTC enrichment, isolation or detection methods used by CTC cfDNA-RNA 2015 participants, in their CTC studies (Study 1)

4.19. Future CTC Enrichment, Isolation or Detection Methods

Figure 4.35. Top ten future CTC enrichment, isolation or detection methods anticipated by CTC cfDNA-RNA 2015 participants, in their CTC studies
Table 4.35. Future CTC enrichment, isolation or detection methods anticipated by CTC cfDNA-RNA 2015 participants, in their CTC studies
Figure 4.36. Top ten future CTC enrichment, isolation or detection methods anticipated by CTC cfDNA-RNA 2015 participants, in their CTC studies (Study 1)
Table 4.36. Future CTC enrichment, isolation or detection methods anticipated by CTC cfDNA-RNA 2015 participants, in their CTC studies (Study 1)

4.20. Current Non-Molecular Techniques

Figure 4.37. Top ten current non-molecular techniques used by CTC cfDNA-RNA 2015 participants, in their CTC studies
Table 4.37. Current non-molecular techniques used by CTC cfDNA-RNA 2015 participants, in their CTC studies
Figure 4.38. Top ten current non-molecular techniques used by CTC cfDNA-RNA 2015 participants, in their CTC studies (Study 1)
Table 4.38. Current non-molecular techniques used by CTC cfDNA-RNA 2015 participants, in their CTC studies (Study 1)

4.21. Future Non-Molecular Techniques

Figure 4.39. Top ten future non-molecular techniques anticipated by CTC cfDNA-RNA 2015 participants, in their CTC studies
Table 4.39. Future non-molecular techniques anticipated by CTC cfDNA-RNA 2015 participants, in their CTC studies
Figure 4.40. Top ten future non-molecular techniques anticipated by CTC cfDNA-RNA 2015 participants, in their CTC studies (Study 1)
Table 4.40. Future non-molecular techniques anticipated by CTC cfDNA-RNA 2015 participants, in their CTC studies (Study 1)

4.22. Current Molecular Techniques

Figure 4.41. Top ten current molecular techniques used by CTC cfDNA-RNA 2015 participants, in their CTC studies
Table 4.42. Current molecular techniques used by CTC cfDNA-RNA 2015 participants, in their CTC studies
Figure 4.42. Top ten current molecular techniques used by CTC cfDNA-RNA 2015 participants, in their CTC studies (Study 1)
Table 4.42. Current molecular techniques used by CTC cfDNA-RNA 2015 participants, in their CTC studies (Study 1)

4.23. Future Molecular Techniques

Figure 4.43. Top ten future molecular techniques anticipated by CTC cfDNA-RNA 2015 participants, in their CTC studies
Table 4.43. Future molecular techniques anticipated by CTC cfDNA-RNA 2015 participants, in their CTC studies
Figure 4.44. Top ten future molecular techniques anticipated by CTC cfDNA-RNA 2015 participants, in their CTC studies (Study 1)
Table 4.44. Future molecular techniques anticipated by CTC cfDNA-RNA 2015 participants, in their CTC studies (Study 1)

4.24. Current Molecular Suppliers

Figure 4.45. Top ten current main suppliers of molecular products (systems, kits, reagents) relating to
Table 4.45. Current main suppliers of molecular products (systems, kits, reagents) relating to Figure 4.46. Top ten current main suppliers of molecular products (systems, kits, reagents) relating to (Study 1)
Table 4.46. Current main suppliers of molecular products (systems, kits, reagents) relating to (Study 1)

4.25. Future Molecular Suppliers

Figure 4.47. Top ten future main suppliers of molecular products (systems, kits, reagents), anticipated by Table 4.47. Future main suppliers of molecular products (systems, kits, reagents), anticipated by Figure 4.48. Top ten future main suppliers of molecular products (systems, kits, reagents), anticipated by (Study 1)
Table 4.48. Future main suppliers of molecular products (systems, kits, reagents), anticipated by (Study 1)


Figure 4.49. Current nucleic acid forms studied by CTC cfDNA-RNA 2015 participants, in their CTC studies Table 4.49. Current nucleic acid forms studied by CTC cfDNA-RNA 2015 participants, in their CTC studies Figure 4.50. Current nucleic acid forms studied by CTC cfDNA-RNA 2015 participants, in their CTC studies (Study 1) Table 4.50. Current nucleic acid forms studied by CTC cfDNA-RNA 2015 participants, in their CTC studies (Study 1)

4.27. Future Nucleic Acid Forms

Figure 4.51. Future nucleic acid forms anticipated by CTC cfDNA-RNA 2015 participants, in their CTC studies Table 4.51. Future nucleic acid forms anticipated by CTC cfDNA-RNA 2015 participants, in their CTC studies Figure 4.52. Future nucleic acid forms anticipated by CTC cfDNA-RNA 2015 participants, in their CTC studies (Study 1) Table 4.52. Future nucleic acid forms anticipated by CTC cfDNA-RNA 2015 participants, in their CTC studies (Study 1)

4.28. Current CTC Molecular Biomarkers

Figure 4.53. Top ten current CTC molecular biomarkers studied by CTC cfDNA-RNA 2015 participants in their CTC studies Table 4.53. Current CTC molecular biomarkers studied by CTC cfDNA-RNA 2015 participants in their CTC studies Figure 4.54. Top ten current CTC molecular biomarkers studied by CTC cfDNA-RNA 2015 participants in their CTC studies (Study 1) Table 4.54. Current CTC molecular biomarkers studied by CTC cfDNA-RNA 2015 participants in their CTC studies (Study 1)

4.29. Future CTC Molecular Biomarkers

Figure 4.55. Top ten future CTC molecular biomarkers anticipated by CTC cfDNA-RNA 2015 participants in their CTC studies Table 4.55. Future CTC molecular biomarkers anticipated by CTC cfDNA-RNA 2015 participants in their CTC studies Figure 4.56. Top ten future CTC molecular biomarkers anticipated by CTC cfDNA-RNA 2015 participants in their CTC studies (Study 1) Table 4.56. Future CTC molecular biomarkers anticipated by CTC cfDNA-RNA 2015 participants in their CTC studies (Study 1)

4.30. Clinical Utilities

Figure 4.57. Top ten clinical utilities of studying CTCs, indicated by participants in CTC cfDNA-RNA 2015 Table 4.57. Clinical utilities of studying CTCs, indicated by participants in CTC cfDNA-RNA 2015 Figure 4.58. Top ten clinical utilities of studying CTCs, indicated by participants in CTC cfDNA-RNA 2015 (Study 1) Table 4.58. Clinical utilities of studying CTCs, indicated by participants in CTC cfDNA-RNA 2015 (Study 1)

4.31. Recent CTC Trends
4.32. Future CTC Trends

Figure 4.61. Top ten future trends in the number of CTC tests (% increase or % decrease), anticipated by CTC cfDNA-RNA 2015 participants
Table 4.61. Future trends in the number of CTC tests (% increase or % decrease), anticipated by CTC cfDNA-RNA 2015 participants
Figure 4.62. Top ten future trends in the number of CTC tests (% increase or % decrease), anticipated by CTC cfDNA-RNA 2015 participants (Study 1)
Table 4.62. Future trends in the number of CTC tests (% increase or % decrease), anticipated by CTC cfDNA-RNA 2015 participants (Study 1)

4.33. CTC Limitations

Figure 4.63. Top ten limitations in the study of CTCs, indicated by CTC cfDNA-RNA 2015 participants
Table 4.63. Limitations in the study of CTCs, indicated by CTC cfDNA-RNA 2015 participants
Figure 4.64. Top ten limitations in the study of CTCs, indicated by CTC cfDNA-RNA 2015 participants (Study 1)
Table 4.64. Limitations in the study of CTCs, indicated by CTC cfDNA-RNA 2015 participants (Study 1)

4.34. Costs

Figure 4.65. Per-patient test costs (including replicates and controls, but excluding instrumentation and overheads) for CTC tests, indicated by CTC cfDNA-RNA 2015 participants
Table 4.65. Per-patient test costs (including replicates and controls, but excluding instrumentation and overheads) for CTC tests, indicated by CTC cfDNA-RNA 2015 participants
Figure 4.66. Per-patient test costs (including replicates and controls, but excluding instrumentation and overheads) for CTC tests, indicated by CTC cfDNA-RNA 2015 participants (Study 1)
Table 4.66. Per-patient test costs (including replicates and controls, but excluding instrumentation and overheads) for CTC tests, indicated by CTC cfDNA-RNA 2015 participants (Study 1)

4.35. CTCs in Drug R&D

Figure 4.67. Use of CTCs in drug R&D, indicated by CTC cfDNA-RNA 2015 participants
Table 4.67. Use of CTCs in drug R&D, indicated by CTC cfDNA-RNA 2015 participants
Figure 4.68. Use of CTCs in drug R&D, indicated by CTC cfDNA-RNA 2015 participants (Study 1)
Table 4.68. Use of CTCs in drug R&D, indicated by CTC cfDNA-RNA 2015 participants (Study 1)

4.36. CTCs and Drug R&D Development Phase

Figure 4.69. Use of CTCs in drug R&D by development phase, indicated by CTC cfDNA-RNA 2015 participants who indicated 'yes' to the previous question (see 4.29)
Table 4.69. Use of CTCs in drug R&D by development phase, indicated by CTC cfDNA-RNA 2015 participants who indicated 'yes' to the previous question (see 4.29)
Figure 4.70. Use of CTCs in drug R&D by development phase, indicated by CTC cfDNA-RNA 2015 participants who indicated 'yes' to the previous question (see 4.29) (Study 1)
Table 4.70. Use of CTCs in drug R&D by development phase, indicated by CTC cfDNA-RNA 2015 participants who indicated 'yes' to the previous question (see 4.29) (Study 1)

4.37. Future use of CTCs in Drug R&D

Figure 4.71. Future use of CTCs in drug R&D by CTC cfDNA-RNA 2015 participants who indicated 'no' to the previous related question (see section 4.29)
Table 4.71. Future use of CTCs in drug R&D by CTC cfDNA-RNA 2015 participants who indicated 'no' to the previous related question (see section 4.29)
Figure 4.72. Future use of CTCs in drug R&D by CTC cfDNA-RNA 2015 participants who indicated 'no' to the previous related question (see section 4.29) (Study 1)
Table 4.72. Future use of CTCs in drug R&D by CTC cfDNA-RNA 2015 participants who indicated 'no' to the
4.38. CTCs in Companion Diagnostics
Figure 4.73. The use of CTCs in the development of companion diagnostics, indicated by CTC cfDNA-RNA 2015 participants
Table 4.73. The use of CTCs in the development of companion diagnostics, indicated by CTC cfDNA-RNA 2015 participants
Figure 4.74. The use of CTCs in the development of companion diagnostics, indicated by CTC cfDNA-RNA 2015 participants (Study 1)
Table 4.74. The use of CTCs in the development of companion diagnostics, indicated by CTC cfDNA-RNA 2015 participants (Study 1)

4.39. CTCs in Future Companion Diagnostics
Figure 4.75. The future use of CTCs in the development of companion diagnostics, anticipated by CTC cfDNA-RNA 2015 participants
Table 4.75. The future use of CTCs in the development of companion diagnostics, anticipated by CTC cfDNA-RNA 2015 participants
Figure 4.76. The future use of CTCs in the development of companion diagnostics, anticipated by CTC cfDNA-RNA 2015 participants (Study 1)
Table 4.76. The future use of CTCs in the development of companion diagnostics, anticipated by CTC cfDNA-RNA 2015 participants (Study 1)

Chapter 5 Circulating Cell-Free DNA And RNA (cfDNA and cfRNA)

5.1. This Chapter
5.2. Role of Participant
Figure 5.1. Role of CTC cfDNA-RNA 2015 participants in the cancer field, who study cfDNA and/or cfRNA in their work.
Table 5.1. Role of CTC cfDNA-RNA 2015 participants in the cancer field, who study cfDNA and/or cfRNA. In their work.
Figure 5.2. Role of CTC cfDNA-RNA 2015 participants in the cancer field, who study cfDNA and/or cfRNA in their work (Study 1)
Table 5.2. Role of CTC cfDNA-RNA 2015 participants in the cancer field, who study cfDNA and/or cfRNA. In their work (Study 1)

5.3. Current Purpose
Figure 5.3. Participant’s top ten current purposes of the study of cfDNA or cfRNA in their work.
Table 5.3. Participant’s current purposes of the study of cfDNA or cfRNA in their work.
Figure 5.4. Participant’s top ten current purposes of the study of cfDNA or cfRNA in their work (Study 1)
Table 5.4. Participant’s current purposes of the study of cfDNA or cfRNA in their work (Study 1)

5.4. Future Purpose
Figure 5.5. The top ten future anticipated purposes of the study of cfDNA or cfRNA in their work.
Table 5.5. The future anticipated purposes of the study of cfDNA or cfRNA in their work.
Figure 5.6. The top ten future anticipated purposes of the study of cfDNA or cfRNA in their work (Study 1)
Table 5.6. The future anticipated purposes of the study of cfDNA or cfRNA in their work (Study 1)

5.5. Current Diseases
Figure 5.7. Top ten current diseases to which participant’s cfDNA or cfRNA studies relate.
Table 5.7. Current diseases to which participant’s cfDNA or cfRNA studies relate.
Figure 5.8. Top ten current diseases to which participant’s cfDNA or cfRNA studies relate (Study 1)
Table 5.8. Current diseases to which participant’s cfDNA or cfRNA studies relate (Study 1)

5.6. Future Diseases
Figure 5.9. Top ten anticipated future diseases to which participant’s cfDNA or cfRNA studies relate
Table 5.9. Anticipated future diseases to which participant’s cfDNA or cfRNA studies relate
Figure 5.10. Top ten anticipated future diseases to which participant’s cfDNA or cfRNA studies relate (Study
1) Table 5.10. Anticipated future diseases to which participant's cfDNA or cfRNA studies relate (Study 1)

5.7. Current Cancers

Figure 5.11. Top ten current cancers to which participant's cfDNA or cfRNA studies relate.
Table 5.11. Current cancers to which participant's cfDNA or cfRNA studies relate.
Figure 5.12. Top ten current cancers to which participant's cfDNA or cfRNA studies relate (Study 1)
Table 5.12. Current cancers to which participant's cfDNA or cfRNA studies relate (Study 1)

5.8. Future Cancers

Figure 5.13. Top ten anticipated future cancers to which participant's cfDNA or cfRNA studies relate
Table 5.13. Anticipated future cancers to which participant's cfDNA or cfRNA studies relate
Figure 5.14. Top ten anticipated future cancers to which participant's cfDNA or cfRNA studies relate (Study 1)
Table 5.14. Anticipated future cancers to which participant's cfDNA or cfRNA studies relate (Study 1)

5.9. Current Sample Types

Figure 5.15. Top ten current sample types to which participant's cfDNA or cfRNA studies relate.
Table 5.15. Current sample types to which participant's cfDNA or cfRNA studies relate.
Figure 5.16. Top ten current sample types to which participant's cfDNA or cfRNA studies relate (Study 1)
Table 5.16. Current sample types to which participant's cfDNA or cfRNA studies relate (Study 1)

5.10. Future Sample Types

Figure 5.17. Top ten anticipated future sample types to which participant's cfDNA or cfRNA studies relate
Table 5.17. Anticipated future sample types to which participant's cfDNA or cfRNA studies relate
Figure 5.18. Top ten anticipated future sample types to which participant's cfDNA or cfRNA studies relate (Study 1)
Table 5.18. Anticipated future sample types to which participant's cfDNA or cfRNA studies relate (Study 1)

5.11. Current Molecular Techniques

Figure 5.19. Top ten current molecular techniques to which participant's cfDNA or cfRNA studies relate.
Table 5.19. Current molecular techniques to which participant's cfDNA or cfRNA studies relate.
Figure 5.20. Top ten current molecular techniques to which participant's cfDNA or cfRNA studies relate (Study 1)
Table 5.20. Current molecular techniques to which participant's cfDNA or cfRNA studies relate (Study 1)

5.12. Future Molecular Techniques

Figure 5.21. Top ten anticipated future molecular techniques to which participant's cfDNA or cfRNA studies relate
Table 5.21. Anticipated future molecular techniques to which participant's cfDNA or cfRNA studies relate
Figure 5.22. Top ten anticipated future molecular techniques to which participant's cfDNA or cfRNA studies relate (Study 1)
Table 5.22. Anticipated future molecular techniques to which participant's cfDNA or cfRNA studies relate (Study 1)

5.13. Current Molecular Suppliers

Figure 5.23. Top ten current main suppliers of molecular products (systems, kits, reagents) relating to
Table 5.23. Current main suppliers of molecular products (systems, kits, reagents) relating to
Figure 5.24. Top ten current main suppliers of molecular products (systems, kits, reagents) relating to (Study 1)
Table 5.24. Current main suppliers of molecular products (systems, kits, reagents) relating to (Study 1)

5.14. Future Molecular Suppliers

Figure 5.25. Top ten future main suppliers of molecular products (systems, kits, reagents), anticipated by
Table 5.25. Future main suppliers of molecular products (systems, kits, reagents), anticipated by
Figure 5.26. Top ten future main suppliers of molecular products (systems, kits, reagents), anticipated by
Table 5.26. Future main suppliers of molecular products (systems, kits, reagents), anticipated by (Study 1)

5.15. Enrichment or Isolation

5.16. Current Nucleic Acid Forms

Figure 5.27. Current nucleic acid forms studied by CTC cfDNA-RNA 2015 participants, in their cfDNA and/or cfRNA studies
Table 5.27. Current nucleic acid forms studied by CTC cfDNA-RNA 2015 participants, in their cfDNA and/or cfRNA studies
Figure 5.28. Current nucleic acid forms studied by CTC cfDNA-RNA 2015 participants, in their cfDNA and/or cfRNA studies (Study 1)
Table 5.28. Current nucleic acid forms studied by CTC cfDNA-RNA 2015 participants, in their cfDNA and/or cfRNA studies (Study 1)

5.17. Future Nucleic Acid Forms

Figure 5.29. Future nucleic acid forms anticipated by CTC cfDNA-RNA 2015 participants, in their cfDNA and/or cfRNA studies
Table 5.29. Future nucleic acid forms anticipated by CTC cfDNA-RNA 2015 participants, in their cfDNA and/or cfRNA studies
Figure 5.30. Future nucleic acid forms anticipated by CTC cfDNA-RNA 2015 participants, in their cfDNA and/or cfRNA studies (Study 1)
Table 5.30. Future nucleic acid forms anticipated by CTC cfDNA-RNA 2015 participants, in their cfDNA and/or cfRNA studies (Study 1)

5.18. Current cfDNA and/or cfRNA Molecular Biomarkers

Figure 5.31. Top ten current cfDNA and/or cfRNA molecular biomarkers studied by CTC cfDNA-RNA 2015 participants in their cfDNA and/or cfRNA studies
Table 5.31. Current cfDNA and/or cfRNA molecular biomarkers studied by CTC cfDNA-RNA 2015 participants in their cfDNA and/or cfRNA studies
Figure 5.32. Top ten current cfDNA and/or cfRNA molecular biomarkers studied by CTC cfDNA-RNA 2015 participants in their cfDNA and/or cfRNA studies (Study 1)
Table 5.32. Current cfDNA and/or cfRNA molecular biomarkers studied by CTC cfDNA-RNA 2015 participants in their cfDNA and/or cfRNA studies (Study 1)

5.19. Future cfDNA and/or cfRNA Molecular Biomarkers

Figure 5.33. Top ten future cfDNA and/or cfRNA molecular biomarkers anticipated by CTC cfDNA-RNA 2015 participants in their cfDNA and/or cfRNA studies
Table 5.33. Future cfDNA and/or cfRNA molecular biomarkers anticipated by CTC cfDNA-RNA 2015 participants in their cfDNA and/or cfRNA studies
Figure 5.34. Top ten future cfDNA and/or cfRNA molecular biomarkers anticipated by CTC cfDNA-RNA 2015 participants in their cfDNA and/or cfRNA studies (Study 1)
Table 5.34. Future cfDNA and/or cfRNA molecular biomarkers anticipated by CTC cfDNA-RNA 2015 participants in their cfDNA and/or cfRNA studies (Study 1)

5.20. Clinical Utilities

Figure 5.35. Top ten clinical utilities of studying cfDNA and/or cfRNA, indicated by participants in CTC cfDNA-RNA 2015
Table 5.35. Clinical utilities of studying cfDNA and/or cfRNA, indicated by participants in CTC cfDNA-RNA 2015
Figure 5.36. Top ten clinical utilities of studying cfDNA and/or cfRNA, indicated by participants in CTC cfDNA-RNA 2015 (Study 1)
Table 5.36. Clinical utilities of studying cfDNA and/or cfRNA, indicated by participants in CTC cfDNA-RNA 2015 (Study 1)

5.21. Recent cfDNA and/or cfRNA Trends

Figure 5.37. Top ten recent trends in the number of cfDNA and/or cfRNA tests (% increase or % decrease),
indicated by CTC cfDNA-RNA 2015 participants
Table 5.37. Recent trends in the number of cfDNA and/or cfRNA tests (% increase or % decrease), indicated by CTC cfDNA-RNA 2015 participants
Figure 5.38. Top ten recent trends in the number of cfDNA and/or cfRNA tests (% increase or % decrease), indicated by CTC cfDNA-RNA 2015 participants (Study 1)
Table 5.38. Recent trends in the number of cfDNA and/or cfRNA tests (% increase or % decrease), indicated by CTC cfDNA-RNA 2015 participants (Study 1)

5.22. Future cfDNA and/or cfRNA Trends

Figure 5.39. Top ten future trends in the number of cfDNA and/or cfRNA tests (% increase or % decrease), anticipated by CTC cfDNA-RNA 2015 participants
Table 5.39. Future trends in the number of cfDNA and/or cfRNA tests (% increase or % decrease), anticipated by CTC cfDNA-RNA 2015 participants
Figure 5.40. Top ten future trends in the number of cfDNA and/or cfRNA tests (% increase or % decrease), anticipated by CTC cfDNA-RNA 2015 participants (Study 1)
Table 5.40. Future trends in the number of cfDNA and/or cfRNA tests (% increase or % decrease), anticipated by CTC cfDNA-RNA 2015 participants (Study 1)

5.23. cfDNA and/or cfRNA Limitations

Figure 5.41. Top ten limitations in the study of cfDNA and/or cfRNA, indicated by CTC cfDNA-RNA 2015 participants
Table 5.41. Limitations in the study of cfDNA and/or cfRNA, indicated by CTC cfDNA-RNA 2015 participants
Figure 5.42. Top ten limitations in the study of cfDNA and/or cfRNA, indicated by CTC cfDNA-RNA 2015 participants (Study 1)
Table 5.42. Limitations in the study of cfDNA and/or cfRNA, indicated by CTC cfDNA-RNA 2015 participants (Study 1)

5.24. Costs

Figure 5.43. Per-patient test costs (including replicates and controls, but excluding instrumentation and overheads) for cfDNA and/or cfRNA tests, indicated by CTC cfDNA-RNA 2015 participants
Table 5.43. Per-patient test costs (including replicates and controls, but excluding instrumentation and overheads) for cfDNA and/or cfRNA tests, indicated by CTC cfDNA-RNA 2015 participants
Figure 5.44. Per-patient test costs (including replicates and controls, but excluding instrumentation and overheads) for cfDNA and/or cfRNA tests, indicated by CTC cfDNA-RNA 2015 participants (Study 1)
Table 5.44. Per-patient test costs (including replicates and controls, but excluding instrumentation and overheads) for cfDNA and/or cfRNA tests, indicated by CTC cfDNA-RNA 2015 participants (Study 1)

5.25. cfDNA and/or cfRNA in Drug R&D

Figure 5.45. Use of cfDNA and/or cfRNA in drug R&D, indicated by CTC cfDNA-RNA 2015 participants
Table 5.45. Use of cfDNA and/or cfRNA in drug R&D, indicated by CTC cfDNA-RNA 2015 participants
Figure 5.46. Use of cfDNA and/or cfRNA in drug R&D, indicated by CTC cfDNA-RNA 2015 participants (Study 1)
Table 5.46. Use of cfDNA and/or cfRNA in drug R&D, indicated by CTC cfDNA-RNA 2015 participants (Study 1)

5.26. cfDNA and/or cfRNA and Drug R&D Development Phase

Figure 5.47. Use of cfDNA and/or cfRNA in drug R&D by development phase, indicated by CTC cfDNA-RNA 2015 participants who indicated 'yes' to the previous question (see 5.27)
Table 5.47. Use of CTCs in drug R&D by development phase, indicated by CTC cfDNA-RNA 2015 participants who indicated 'yes' to the previous question (see 5.27)
Figure 5.48. Use of cfDNA and/or cfRNA in drug R&D by development phase, indicated by CTC cfDNA-RNA 2015 participants who indicated 'yes' to the previous question (see 5.27) (Study 1)
Table 5.48. Use of CTCs in drug R&D by development phase, indicated by CTC cfDNA-RNA 2015 participants who indicated 'yes' to the previous question (see 5.27) (Study 1)

5.27. Future use of cfDNA and/or cfRNA in Drug R&D

Figure 5.49. Future use of cfDNA and/or cfRNA in drug R&D by CTC cfDNA-RNA 2015 participants who indicated 'no' to the previous related question (see section 5.27)
Table 5.49. Future use of cfDNA and/or cfRNA in drug R&D by CTC cfDNA-RNA 2015 participants who indicated ‘no’ to the previous related question (see section 5.27)

Figure 5.50. Future use of cfDNA and/or cfRNA in drug R&D by CTC cfDNA-RNA 2015 participants who indicated ‘no’ to the previous related question (see section 5.27) (Study 1)

Table 5.50. Future use of cfDNA and/or cfRNA in drug R&D by CTC cfDNA-RNA 2015 participants who indicated ‘no’ to the previous related question (see section 5.27) (Study 1)

5.28. cfDNA and/or cfRNA in Companion Diagnostics

Figure 5.51. The use of cfDNA and/or cfRNA in the development of companion diagnostics, indicated by CTC cfDNA-RNA 2015 participants

Table 5.51. The use of cfDNA and/or cfRNA in the development of companion diagnostics, indicated by CTC cfDNA-RNA 2015 participants

Figure 5.52. The use of cfDNA and/or cfRNA in the development of companion diagnostics, indicated by CTC cfDNA-RNA 2015 participants (Study 1)

Table 5.52. The use of cfDNA and/or cfRNA in the development of companion diagnostics, indicated by CTC cfDNA-RNA 2015 participants (Study 1)

5.29. cfDNA and/or cfRNA in Future Companion Diagnostics

Figure 5.53. The future use of cfDNA and/or cfRNA in the development of companion diagnostics, anticipated by CTC cfDNA-RNA 2015 participants (for those who answered ‘no’ to the previous questions (see 5.30)

Table 5.53. The future use of cfDNA and/or cfRNA in the development of companion diagnostics, anticipated by CTC cfDNA-RNA 2015 participants (for those who answered ‘no’ to the previous questions (see 5.30)

Figure 5.54. The future use of cfDNA and/or cfRNA in the development of companion diagnostics, anticipated by CTC cfDNA-RNA 2015 participants (for those who answered ‘no’ to the previous questions (see 5.30) (Study 1)

Table 5.54. The future use of cfDNA and/or cfRNA in the development of companion diagnostics, anticipated by CTC cfDNA-RNA 2015 participants (for those who answered ‘no’ to the previous questions (see 5.30) (Study 1)

Chapter 6 Exosomes

6.1. This Chapter

6.2. Current study of Exosomes

Figure 6.1. The study of exosomes by CTC cfDNA-RNA 2015 participants

Table 6.1. The study of exosomes by CTC cfDNA-RNA 2015 participants

Figure 6.2. The study of exosomes by CTC cfDNA-RNA 2015 participants (Study 1)

Table 6.2. The study of exosomes by CTC cfDNA-RNA 2015 participants (Study 1)

6.3. Future study of Exosomes

Figure 6.3. The future study of exosomes, anticipated by CTC cfDNA-RNA 2015 participants (for those who answered ‘no’ to the previous question, see 6.3)

Table 6.3. The future study of exosomes, anticipated by CTC cfDNA-RNA 2015 participants (for those who answered ‘no’ to the previous question, see 6.3)

Figure 6.4. The future study of exosomes, anticipated by CTC cfDNA-RNA 2015 participants (for those who answered ‘no’ to the previous question, see 6.3) (Study 1)

Table 6.4. The future study of exosomes, anticipated by CTC cfDNA-RNA 2015 participants (for those who answered ‘no’ to the previous question, see 6.3) (Study 1)

6.4. Disease Areas

Figure 6.5. Disease areas of of CTC cfDNA-RNA 2015 participants, to which their exosome studies relate

Table 6.5. Disease areas of of CTC cfDNA-RNA 2015 participants, to which their exosome studies relate

Figure 6.6. Disease areas of of CTC cfDNA-RNA 2015 participants, to which their exosome studies relate (Study 1)

Table 6.6. Disease areas of of CTC cfDNA-RNA 2015 participants, to which their exosome studies relate (Study 1)
6.5. Isolation of Exosomes

Chapter 7 Clinical Trials

7.1. This Chapter

7.2. Clinical Trials

Figure 7.1. Clinical Trials incorporating the study of CTCs or cfDNA/cfRNA
Table 7.1. Clinical Trials incorporating the study of CTCs or cfDNA/cfRNA
Figure 7.2. CTC or cfDNA/cfRNA Clinical Trials by Recruitment Stage
Table 7.2. CTC or cfDNA/cfRNA Clinical Trials by Recruitment Stage

7.3. CTC vs. Circulating Cell-Free Nucleic Acids (cfDNA and cfRNA)

Figure 7.3. CTCs Vs. cfDNA/cfRNA in Clinical Trials
Table 7.3. CTCs Vs. cfDNA/cfRNA in Clinical Trials

7.4 Pharma Companies Studying CTCs or cfDNA/cfRNA in Clinical Trials

Figure 7.4. Pharma Companies Progressing Clinical Trials incorporating the study of CTCs or cfDNA/cfRNA
Table 7.4. Pharma Companies Progressing Clinical Trials incorporating the study of CTCs or cfDNA/cfRNA
Figure 7.5. CTCs Vs. cfDNA/cfRNA in Clinical Trials by Pharma Companies
Table 7.5. CTCs Vs. cfDNA/cfRNA in Clinical Trials by Pharma Companies

7.5 Cancer Types

Figure 7.6. Pharma Companies Progressing Clinical Trials incorporating the study of CTCs or cfDNA/cfRNA, by Cancer Type
Table 7.6. Pharma Companies Progressing Clinical Trials incorporating the study of CTCs or cfDNA/cfRNA, by Cancer Type
Figure 7.7. CTCs Vs. cfDNA/cfRNA in Clinical Trials by Cancer Type
Table 7.7. CTCs Vs. cfDNA/cfRNA in Clinical Trials by Cancer Type

7.6 Approved Drugs and CTCs or cfDNA/cfRNA Clinical Trials

Figure 7.8. Approved Drugs in Clinical Trials incorporating the study of CTCs or cfDNA/cfRNA, 2012-2015
Table 7.8. Approved Drugs in Clinical Trials incorporating the study of CTCs or cfDNA/cfRNA, 2012-2015

7.7 CTC or cfDNA/cfRNA by Clinical Trial Phase

Figure 7.9. Clinical Trials incorporating the study of CTCs or cfDNA/cfRNA, by Pharma Company and Clinical Trials Phase
Table 7.9. Clinical Trials incorporating the study of CTCs or cfDNA/cfRNA, by Pharma Company and Clinical Trials Phase

Chapter 8 Discussion

8.1 Discussion

Ordering:
Order Online - http://www.researchandmarkets.com/reports/4043090/

Order by Fax - using the form below

Order by Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
**Fax Order Form**

To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit [http://www.researchandmarkets.com/contact/](http://www.researchandmarkets.com/contact/)

**Order Information**
Please verify that the product information is correct.

<table>
<thead>
<tr>
<th>Product Name:</th>
<th>Liquid Biopsy Markets: Global Analysis and Opportunity Evaluation 2016 - 2020</th>
</tr>
</thead>
<tbody>
<tr>
<td>Web Address:</td>
<td><a href="http://www.researchandmarkets.com/reports/4043090/">http://www.researchandmarkets.com/reports/4043090/</a></td>
</tr>
<tr>
<td>Office Code:</td>
<td>SC</td>
</tr>
</tbody>
</table>

**Product Format**
Please select the product format and quantity you require:

- **Electronic (PDF)**
- **Enterprisewide**: USD 5942

*The price quoted above is only valid for 30 days. Please submit your order within that time frame to avail of this price as all prices are subject to change.

**Contact Information**
Please enter all the information below in **BLOCK CAPITALS**

<table>
<thead>
<tr>
<th>Title:</th>
<th>Mr ☐ Mrs ☐ Dr ☐ Miss ☐ Ms ☐ Prof ☐</th>
</tr>
</thead>
<tbody>
<tr>
<td>First Name:</td>
<td></td>
</tr>
<tr>
<td>Last Name:</td>
<td></td>
</tr>
<tr>
<td>Email Address: *</td>
<td></td>
</tr>
<tr>
<td>Job Title:</td>
<td></td>
</tr>
<tr>
<td>Organisation:</td>
<td></td>
</tr>
<tr>
<td>Address:</td>
<td></td>
</tr>
<tr>
<td>City:</td>
<td></td>
</tr>
<tr>
<td>Postal / Zip Code:</td>
<td></td>
</tr>
<tr>
<td>Country:</td>
<td></td>
</tr>
<tr>
<td>Phone Number:</td>
<td></td>
</tr>
<tr>
<td>Fax Number:</td>
<td></td>
</tr>
</tbody>
</table>

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:
Account number 833 130 83
Sort code 98-53-30
Swift code ULSBIE2D
IBAN number IE78ULSB98533083313083
Bank Address Ulster Bank,
27-35 Main Street,
Blackrock,
Co. Dublin,
Ireland.

If you have a Marketing Code please enter it below:

Marketing Code: 

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World